Form 4: Day One Biopharmaceuticals CEO Jeremy Bender Reports Changes in Beneficial Ownership

CEO Jeremy Bender reports changes in beneficial ownership of Day One Biopharmaceuticals stock due to annuity payments from grantor retained annuity trusts to a revocable trust.

Summary

• Jeremy Bender, CEO of Day One Biopharmaceuticals, filed a Form 4 detailing changes in his beneficial ownership of the company's stock on July 2, 2024.
• The changes involve the transfer of shares from several Grantor Retained Annuity Trusts (GRATs) to the Bender Revocable Trust.
• These transfers represent annuity payments made by the Jeremy Bender 2022 GRAT, Melissa Bender 2022 GRAT, Jeremy Bender 2023 GRAT, and Melissa Bender 2023 GRAT.
• The transfers were bona fide gifts for no consideration to the Bender Revocable Trust dated January 18, 2017.
• The reported transactions involve multiple transfers of common stock, with some shares being directly held and others indirectly held through the GRATs and the revocable trust.
• As a result of these transactions, Bender's directly and indirectly held shares have changed, with the Bender Revocable Trust now holding a significant portion of the shares.
• The filing also notes that 565,114 shares of the Issuer's Common Stock that the Reporting Person retitled on July 2, 2024.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing changes in stock ownership. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to changes in beneficial ownership by a company insider, which is a common occurrence in publicly traded companies.

Stakeholder Impact

• The changes in beneficial ownership may be of interest to shareholders, but the transactions themselves are related to estate planning and do not directly impact the company's operations.

Key Dates